If you live in Connecticut and are researching compounded semaglutide or compounded tirzepatide, this page is meant to save you some digging. It covers how telehealth access works in the state, what Connecticut’s telehealth statute actually requires, the pharmacy rule that matters most for injectable compounded medication, what changed under federal law in 2025, what treatment costs at Gentle Health, and how other providers serving the state compare on their own published prices. One disclosure up front: this site is operated by Gentle Health, a telehealth practice offering compounded GLP-1 treatment, so we have an interest in the subject. Gentle Health appears in the provider comparison on the same terms as every other provider listed, and every price links to the page it came from.
How compounded GLP-1 access works in Connecticut
Connecticut does not require you to visit a clinic in person to be evaluated for a GLP-1 prescription. Telehealth is held to the same standard of care as in-person care, which means a physician can evaluate you remotely, decide whether treatment is appropriate, and prescribe if it is.
Here is what that looks like for a Gentle Health patient in Connecticut:
- Complete a medical intake. You answer questions about your health history, current medications and goals.
- Physician review. In Connecticut, a licensed physician reviews your medical intake online and decides whether a video visit is needed. That physician is James Simmons, MD, who is licensed to practice in Connecticut (license 086482, verifiable through the Connecticut eLicense lookup maintained for the Connecticut Medical Examining Board and the Department of Public Health). He evaluates every Connecticut patient individually, and not everyone who applies is approved.
- Prescription and fulfillment. If treatment is appropriate, the prescription goes to a licensed compounding pharmacy and the medication ships to your Connecticut address, from Greenwich to Norwich.
- Ongoing care. Dosing is reviewed and adjusted over time, and you can reach out between refills with questions or side-effect concerns.
Eligibility details and license verification for Connecticut are on our Connecticut page. We use two workflows for an initial prescribing decision, an asynchronous clinician review or a scheduled video visit first, and how our initial prescribing process varies by state explains the difference between them in general terms.
The whole arrangement is cash-pay. Gentle Health does not bill insurance.
Connecticut rules worth knowing
Two regulators shape how compounded GLP-1s reach patients here: the Connecticut Medical Examining Board, within the Department of Public Health, which governs prescribers, and the Commission of Pharmacy, within the Department of Consumer Protection’s Drug Control Division, which governs the pharmacies that compound and dispense.
Connecticut’s telehealth statute sets out what a provider owes you at the first visit. Conn. Gen. Stat. § 19a-906 requires a telehealth provider to conform to “the standard of care applicable to the telehealth provider’s profession and expected for in-person care as appropriate to the patient’s age and presenting condition.” The statute is unusually concrete about the first interaction. The provider must give you their license number and contact information, must obtain your consent to receive care by telehealth after explaining the treatment methods and limitations, and must document that notice and consent in your health record. The provider must also have access to, or knowledge of, your medical history and health record, including the name and address of your primary care provider if you have one, and must communicate through real-time interactive technology or store-and-forward technologies. The statute expressly excludes facsimile, texting and electronic mail from what counts as telehealth.
Read that list again as a consumer, because it is a ready-made test. A Connecticut telehealth provider who will not tell you their license number is not meeting a courtesy standard; they are not meeting the statute. Dr. Simmons’s Connecticut license number is 086482 and it is on this page, on our Connecticut page, and in the state’s public lookup.
The same section restricts prescribing of schedule I, II and III controlled substances by telehealth, with a narrow exception for certain non-opioid treatment. Semaglutide and tirzepatide are not controlled substances, so that particular restriction does not apply to them. Every other requirement in the section still does, including the first-interaction duties above and the standard of care.
Connecticut is now a full participant in the Interstate Medical Licensure Compact. Connecticut’s Compact legislation passed in May 2022, and on March 15, 2026 the Compact Commission announced that Connecticut had gone live as a State of Principal Licensure, completing the second phase so that qualifying Connecticut physicians can also seek expedited licensure in other member states (Interstate Medical Licensure Compact Commission). The Compact gives qualified physicians in good standing an expedited route to full licensure in member states. It does not lower the bar: a Compact-issued license is an ordinary, full state license, and the physician is subject to Connecticut law and the Connecticut board like any other licensee.
The pharmacy rule that matters most here concerns sterile compounding. Injectable compounded medication is a sterile preparation, and Connecticut pays specific attention to it. Under Conn. Gen. Stat. § 20-627, a pharmacy located outside Connecticut that ships, mails or delivers prescription drugs into the state is a nonresident pharmacy and must be registered with the Department of Consumer Protection. Section 20-633b defines a “sterile pharmaceutical” to include injectables, and treats a nonresident pharmacy that dispenses or compounds them as a sterile compounding pharmacy. A nonresident pharmacy must disclose to the Department whether it is dispensing sterile pharmaceuticals in Connecticut. If any sterile pharmaceutical it dispenses is not patient-specific, it must also submit to the Department a copy of the manufacturing license or registration issued by the state where it is licensed, along with any registration issued to it by the FDA.
Dispensing sterile preparations without a patient-specific order carries a second, heavier duty. Conn. Gen. Stat. § 21a-70 defines a “manufacturer” to include “a sterile compounding pharmacy … that dispenses sterile pharmaceuticals without a prescription or a patient-specific medical order”, and no manufacturer may operate until it holds a certificate of registration from the Commissioner of Consumer Protection, renewed annually. Out-of-state manufacturers can normally satisfy Connecticut by filing their FDA registration instead — but the statute writes sterile compounding pharmacies out of that shortcut expressly, so one dispensing non-patient-specific sterile preparations into Connecticut needs the Connecticut certificate itself.
The practical line for a patient: a compounded GLP-1 dispensed against your own prescription does not put the pharmacy in that category. The duty attaches to pharmacies producing sterile preparations without an individual order, which is the same patient-specific distinction the federal rules turn on.
The distinction embedded in that rule is the same one that governs compounded GLP-1s federally: a preparation made for an identified individual patient under a prescription is treated differently from product made in advance for general sale. It is a fair question to put to any provider: which pharmacy fills this, is it licensed to ship into Connecticut, and is my prescription patient-specific?
Both federal and Connecticut requirements apply to a compounded GLP-1 prescription here. The federal conditions described below govern what a pharmacy may compound. Connecticut’s own rules sit alongside them: the telehealth statute for the prescriber, and nonresident pharmacy licensing and the sterile compounding requirements above for the pharmacy. If you want to know whether a Connecticut regulator has said anything further about a specific product, the Department of Consumer Protection’s Drug Control Division and the Department of Public Health publish their own guidance, and those are the places to look.
None of this is legal advice. The links above go to the sources so you can read them yourself.
What changed federally in 2025, and why it matters here
The rules governing compounded GLP-1s changed in 2025, and most summaries get the dates wrong.
For Section 503A’s essentially-a-copy analysis, while a drug sits on the FDA shortage list, it is not treated as commercially available, and the usual restriction on compounding copies of commercially available drugs does not apply. That is why compounded GLP-1s appeared at scale in 2023 and 2024. When the FDA determined the shortages resolved, it gave compounders wind-down periods, and tied their end to pending litigation: they ran to the announced date or the district court’s decision, whichever was longer. The court denied the preliminary injunction motions in Outsourcing Facilities Association v. FDA on March 5, 2025 for tirzepatide and April 24, 2025 for semaglutide. The FDA then stated that for a state-licensed pharmacy or physician compounding under Section 503A, “the period of enforcement discretion … has ended” as of those dates (FDA).
That did not close Section 503A compounding, and the courts did not change the law. What ended was the shortage-based enforcement discretion. Compounding under Section 503A continues, subject to the conditions the statute always imposed. The FDA describes those conditions plainly: the drug is compounded for an individual patient on receipt of a prescription, and the compounder does not compound, regularly or in inordinate amounts, products that are essentially copies of a commercially available drug.
Within that essentially-a-copy analysis there is one patient-specific pathway. A compounded product is not treated as an essential copy where the prescriber determines and documents that it contains a change producing a significant difference for an identified individual patient. That is one route through one condition, not the whole legal test, and every other Section 503A requirement continues to apply alongside it. The FDA has also said it does not currently intend to act against a compounder on the regularly-or-in-inordinate-amounts point where four or fewer prescriptions of that product are filled in a calendar month.
The weight moved off a supply designation and onto your prescriber, the record they keep, and the pharmacy’s compliance with the rest of Section 503A. Connecticut’s own rules turn on a related distinction: its sterile compounding disclosure requirements ask whether a dispensed preparation is patient-specific.
Compounded semaglutide in Connecticut
Semaglutide is a GLP-1 receptor agonist, a medication that mimics a gut hormone involved in appetite regulation and blood sugar control. Compounded semaglutide is a version of that molecule prepared by a licensed compounding pharmacy for an individual patient under a prescription, rather than manufactured by the brand’s maker.
Compounded medications are not FDA-approved. The FDA has not reviewed those specific preparations for safety, effectiveness or quality, and results from trials of the FDA-approved semaglutide products should not be assumed to transfer to them (FDA). Oversight comes from state boards of pharmacy and, for some facilities, federal registration.
Gentle Health offers compounded semaglutide in two forms for Connecticut patients:
- Oral compounded semaglutide: starting at $112 per month. Taken daily, no needles involved.
- Injectable compounded semaglutide: starting at $135 per month. A once-weekly subcutaneous injection.
Both prices are cash-pay and dose-tiered and include the medical care described above: the evaluation by James Simmons, MD, the prescription if treatment is appropriate, the medication, and ongoing dosing review. There is no separate membership fee and no intro rate that resets upward after the first month.
Whether semaglutide is appropriate for you is a medical question, not a marketing one. Side effects, most commonly gastrointestinal, are real, and treatment is subject to medical evaluation.
Compounded tirzepatide in Connecticut
Tirzepatide works on two receptors rather than one, GLP-1 and GIP, a second gut hormone involved in metabolic regulation. It is the newer of the two molecules, and cash prices run higher than semaglutide almost everywhere it is offered.
Gentle Health offers injectable compounded tirzepatide starting at $169 per month for Connecticut patients, cash-pay and dose-tiered, covering the evaluation, the prescription when appropriate, the compounded medication from a licensed pharmacy, and ongoing care. Once-weekly subcutaneous injection.
The same caveats apply. Compounded tirzepatide is not an FDA-approved product. It is compounded under Section 503A subject to that section’s conditions, including the patient-specific pathway through the essentially-a-copy analysis described above, where the prescriber determines and documents a change producing a significant difference for an identified patient. Trial data generated for the FDA-approved products describe those products, not compounded preparations. Which molecule makes sense, if either, belongs in the medical evaluation.
Provider options in Connecticut: provider comparison
Methodology: providers are listed alphabetically; prices were taken only from each provider’s own public pages on September 18, 2026, and where a provider does not publish a figure we write “See site” rather than estimating. Gentle Health operates this site and appears on the same terms as everyone else. No row is a recommendation.
Gentle Health
- Care model: Telehealth; care by James Simmons, MD
- Compounded semaglutide (cash/mo): From $112 (oral) / from $135 (injectable)
- Compounded tirzepatide (cash/mo): From $169 (injectable)
- Serves Connecticut: Yes
- Insurance: Cash-pay only; insurance not billed
- Source: gentle.health (verified 2026-09-18)
Henry Meds
- Care model: Telehealth; GLP-1 program bundling provider visits, medication and supplies, priced from $179/mo across treatment plans
- Compounded semaglutide (cash/mo): Not published by molecule
- Compounded tirzepatide (cash/mo): Not published; page does not mention tirzepatide
- Serves Connecticut: See site (states not listed on pricing page)
- Insurance: Not required; cash-pay
- Source: henrymeds.com (verified 2026-09-18)
Mochi Health
- Care model: Telehealth; membership plus medication billed separately
- Compounded semaglutide (cash/mo): From $60 medication + $79/mo membership
- Compounded tirzepatide (cash/mo): From $90 medication + $79/mo membership
- Serves Connecticut: See site (“anywhere in the United States”; state list not published)
- Insurance: Insurance accepted for some services; coverage varies
- Source: joinmochi.com (verified 2026-09-18)
OrderlyMeds
- Care model: Telehealth; all-inclusive plans
- Compounded semaglutide (cash/mo): $149/mo ongoing; new-customer starter billed $149 for 2 months
- Compounded tirzepatide (cash/mo): $299/mo ongoing; new-customer starter billed $299 for 2 months
- Serves Connecticut: Yes (site states all 50 states)
- Insurance: Not required; HSA/FSA accepted
- Source: orderlymeds.com (verified 2026-09-18)
Ozari Health
- Care model: Telehealth; clinician review before prescribing
- Compounded semaglutide (cash/mo): See site (not listed on its Connecticut page)
- Compounded tirzepatide (cash/mo): $125/mo on a 3-month starter plan ($375 billed quarterly)
- Serves Connecticut: Yes (states its clinicians hold active Connecticut licenses)
- Insurance: Not required; HSA/FSA accepted
- Source: ozarihealth.com (verified 2026-09-18)
A few reading notes. OrderlyMeds’ starter offers are advertised as a monthly equivalent but billed as a single two-month charge, are limited to new customers, and reset to the ongoing rate afterwards, so the ongoing number is usually the one to budget around. Membership-model providers bill the membership whether or not medication ships that month. Quarterly billing changes the effective monthly figure and the amount you commit to at once. Providers that sell only FDA-approved brand products are out of scope for this comparison, which compares compounded programs. Prices change often; if you spot a stale number, the source links are there, and we will correct promptly.
We computed the whole annual bill for the major programs, every fee included, in compounded GLP-1 programs compared. The full list of states we practice in is on the states we serve.
Frequently asked questions
Is compounded semaglutide legal in Connecticut? Compounded drugs are not FDA-approved, and whether a particular preparation is lawful depends on the compounder meeting every condition Section 503A imposes, not on any single fact. A valid prescription and a licensed pharmacy are necessary but not sufficient on their own. Since the shortage-based enforcement discretion ended in 2025, compounding continues under those statutory conditions, which include compounding for an individual patient on receipt of a prescription and not compounding essentially-copies regularly or in inordinate amounts, with the patient-specific significant-difference pathway described above running through that analysis. Connecticut’s telehealth statute and its nonresident pharmacy and sterile compounding rules apply on top. Ask any provider which pharmacy fills the prescription and whether it is registered as a nonresident pharmacy in Connecticut.
Do I need an in-person visit before a Connecticut telehealth provider can prescribe? No. Conn. Gen. Stat. § 19a-906 holds telehealth to the same standard of care as in-person care rather than requiring a prior office visit. What the statute does require is that the provider give you their license number and contact information, obtain your consent to telehealth care after explaining the treatment methods and limitations and document that consent in your health record, have access to or knowledge of your medical history and health record, and communicate through real-time interactive or store-and-forward technology rather than fax, text or email. Its schedule I, II and III controlled-substance restriction does not apply to semaglutide or tirzepatide, which are not controlled substances; every other requirement in the section does.
Who provides the medical care at Gentle Health for Connecticut patients, and can I check the license? James Simmons, MD, who holds Connecticut license 086482, verifiable through the state eLicense lookup. He conducts the evaluation, decides whether treatment is appropriate, prescribes when it is, and manages dosing over time. There is no rotating panel; the physician you start with is the physician who manages your care. Connecticut’s telehealth statute entitles you to that license number at your first visit, and board lookups are free and public.
Current Gentle Health dose tiers and pricing
Gentle Health pricing depends on the dose tier prescribed by your clinician. Current monthly prices are:
Oral compounded semaglutide
| Tier | Daily dose | Monthly price |
|---|---|---|
| Starting | 2-4 mg/day | $112/mo |
| Medium | >4-8 mg/day | $189/mo |
| High dose | >8-12 mg/day | $258/mo |
Injectable compounded semaglutide
| Tier | Weekly dose | Monthly price |
|---|---|---|
| Starting | 0.24-0.48 mg/wk | $135/mo |
| Medium | >0.48-1.2 mg/wk | $159/mo |
| High dose | >1.2-2.4 mg/wk | $199/mo |
Injectable compounded tirzepatide
| Tier | Weekly dose | Monthly price |
|---|---|---|
| Starting | 2.5-5 mg/wk | $169/mo |
| Medium | >5-10 mg/wk | $219/mo |
| High dose | >10-15 mg/wk | $269/mo |
Medication, the initial review by a licensed clinician, video visits and messaging, and overnight refrigerated shipping are included. There is no separate membership fee, and HSA and FSA cards are accepted. Your clinician determines the appropriate medication and dose; the monthly price changes if the prescribed dose moves into a different tier.
Gentle Health does not sell Ozempic, Wegovy, Mounjaro or Zepbound. We offer compounded semaglutide and tirzepatide, which are different products, and Gentle Health is not affiliated with or endorsed by Novo Nordisk or Eli Lilly.
By James Simmons, MD
Compounded medications are not FDA-approved. Treatment subject to medical evaluation.